Arius and Avid Bioservices sign manufacturing agreement
Avid has begun manufacturing a supply of the drug for human clinical trials which Arius plans to initiate in 2008. Arius has also scheduled a pre-IND meeting with
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.